A technology investor with a background in teaching business in Belgium and across Europe, Jean-Jacques Degroof seeks out tech companies with the potential to grow and outperform. Having completed graduate studies at the Massachusetts Institute of Technology (MIT), Jean-Jacques Degroof maintains a close watch on companies such as the biotech startup Kytopen, which have significantly benefitted from the innovation-supportive culture at MIT.
In May 2023, Kytopen announced that it was launching the early access Flowfect Discover program for its high-throughput genome and cellular engineering technologies. Utilizing Flowfect enables researchers to engineer cells precisely and efficiently. In a few minutes, researchers can generate as many as 96 samples of complex genetic engineering materials, spanning mRNA, CRISPR, and DNA.
A key benefit of the Flowfect Discover platform is enabling cell therapy developers and researchers to understand novel therapies and optimize delivery before shifting to larger-scale development. The approach is described as saving time and costs and, in the process, enhancing drug discovery capacities, although at present Kytopen technologies are not yet employed in clinical or diagnostic procedures.
